当前位置: 首页 > 期刊 > 《世界华人消化杂志》 > 2002年第2期
编号:10693564
丙型肝炎病毒NS2基因酵母双杂交“饵”载体构建及表达
http://www.100md.com 2002年2月15日 《世界华人消化杂志》 2002年第2期
     李克, 王琳, 成军, 陆荫英, 张玲霞, 李莉, 刘妍, 段惠娟,中国人民解放军第302医院传染病研究所基因治疗研究中心 北京市 100039

    李克, 男,河北省宁晋人,汉族,博士研究生,主要从事传染病的临床与基础研究工作.

    国家自然科学基金资助课题,No.C39970674

    项目负责人 成军,100039,北京市丰台路26号,中国人民解放军第三0二医院传染病研究所基因治疗研究中心. cj@GeneTherapy.com.cn

    电话: 010-66933392 传真: 010-63801283

    收稿日期 2002-01-15 接受日期 2002-02-05

    Expression of NS2 gene of hepatitis C virus from yeast two hybrid'bait' vector in yeast

    
Ke Li, Lin Wang, Jun Cheng, Yin-Ying Lu, Ling-Xia Zhang, Li Li, Yan L iu, Hui-Juan Duan

    Ke Li, Lin Wang, Jun Cheng, Yin-Ying Lu, Ling-Xia Zhang, Li Li, Ya n Liu, Hui-Juan Duan,Gene Therapy Research Center, Institute of Infectious Dis eases, 26 Fengtai Road, 100039 Beijing, China

    Supported by the national Natural Scientific Foundation, No. C39970674

    Correspondence to: Dr.Jun Cheng, Gene Therapy Research Center, I nstitute of Infectious Diseases, 26 Fengtai Road, 100039 Beijing, China. cj@Ge neTherapy.com.cn

    Received 2002-01-15 Accepted 2002-02-05

    Abstract

    AIM:
The function of HCV NS2 is very complicated. HCV NS2 prot ein plays an important role in processing of polyprotein and replication of HCV ,but the effects of NS2 protein on human hepatocytes are elusive. In the report we investigate the gene expression of HCV NS2 from yeast two hybrid 'bait' plas mid in yeast for study of NS2 protein interacting with proteins of hepatocytes.

    METHODS:PCR was performed to amplify the gene of HCV NS2 from th e plasmid pBRTM/HCV containing the whole fragment of HCV and the gene was cloned into pGEM-T vector. The gene of HCV NS2 was cut from pGEM-T vector and cloned into yeast expression plasmid pGBKT7, then pGBKT7-NS2 was transformed into yea st AH109. The yeast protein was isolated and analyzed with sodium dodecyl sulfat e-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting.

    RESULTS:HCV NS2 gene was successfully cloned into pGBKT7 named p GBKT7-NS2. The results of SDS-PAGE and Western blotting assay showed (1)the mo lecular weight of the expressed product was about 23000Da, (2) HCV NS2 protein w as existed within yeast cells and production of NS2 protein is as much as 4% of total protein in yeast cells.

    CONCLUSION:The findings suggested that HCV NS2 was succes sfully expressed in yeast system. which pave the way for further studying of the function of HCV NS2 protein.

    Li K,Wang L,Cheng J,Zhang LX,Lu YY,Li L,Liu Y,Duan HJ.Gene Therapy Res earch Center,Institute of Infectious Diseases, Expression of NS2 gene of hepatit is C virus from yeast two hybrid'bait' vector in yeast.Shijie Huaren Xiaohua Zaz hi 2002;10(2):129-132

    

    目的:
丙型肝炎病毒NS2蛋白在病毒蛋白加工中起到自裂蛋白酶的作用 ,但是对人体的作用还不清楚.为探讨丙型肝炎病毒(HCV)非结构蛋白NS2的功能,在真核生物酵母细胞中表达HCV NS2基因.

    方法:用聚合酶链反应(PCR)的方法以HCV全长质粒pBRTM/*!HCV-1为模 板扩增HCV NS2基因,克隆到pGEM-T载体中,双酶切后回收连接到酵母表达质粒pGBKT7中表 达.提取酵母蛋白质,进行十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和Western 免疫印迹分析.

    结果:成功构建HCV NS2基因酵母表达载体称为pGBKT7-NS2,Western 免 疫印迹显示了HCV NS2在酵母细胞中表达.表达产物在胞内存在,相对分子质量23kD左右, 表达量占细胞总蛋白的4%左右.

    结论:我们成功在酵母细胞中表达了HCV NS2蛋白.为以后研究NS2蛋白对 人体的作用打下了基础.

    李克, 王琳, 成军, 陆荫英,张玲霞,李莉, 刘妍, 段惠娟. 丙型肝炎病毒NS2基因 酵母双杂交“饵”载体构建及表达.

    世界华人消化杂志 2002;10(2):129-132

    0 引言丙型肝炎病毒(HCV)是输血后肝炎的主要病原体[1,2],可以引起肝硬化、肝癌[3-8].此包膜病毒的基因组是单链正义大约9500个核苷酸编码3010-3011氨基酸的 多蛋白前体,基因顺序如下:C-E1-E2-p7-NS2-NS3-NS4a-NS4b-NS5a-NS5b[9 -15].HCV NS2蛋白是推定的非结构蛋白,名字的来源是相应于黄病毒及虫媒病毒的NS2 蛋白.NS2蛋白是分子量为Mr23000的穿膜蛋白质[16],在HCV-1株中,由276 9-3419碱基表达的217个氨基酸,氨基末端的加工,是由宿主细胞提供的裂解酶,羧基末端 加工,是NS2本身一部分及NS3一部分形成的自身裂解蛋白酶所催化[17].NS2-NS3 蛋白酶可能是一种金属蛋白酶[18,19].为了进一步研究此蛋白与人体细胞的相互 作用,我们构建酵母双杂交表达载体并在酵母细胞中表达了NS2蛋白基因.

    1 材料和方法

    1.1 材料
①菌株、载体、酵母:DH5α本室保种,酵母 AH109及载体pGBKT7购自Clontech公司. pGEM-T载体购自Promega公司.②主要试剂:Taq DN A 聚合酶购自MBI公司,T4 DNA连接酶、EcoRI和BamHI购自宝生物公司.c-myc 单克隆抗体本室自制,由购自ATCC的1-9E10.2杂交瘤产生.辣根过氧化物酶酶标羊抗鼠IgG为中山生物公司产品.醋酸锂购自Sigma公司.丙稀酰胺、N,N'-亚甲双丙烯酰胺为Promega公司产品,TEMED为宝林曼公司产品.IPTG及X-β-Gal购自Promega公司.③培养基:胰蛋白胨、酵母提取物为OXOID公司产品.酵母YPD培养基、SD/-Trp培养基购自Clontech公司,半硫酸腺苷购自Sigma公司.

    1.2 方法 ①HCV NS2蛋白基因的扩增:根据HCV H株的 基因序列,在编码区的上游和下游分别设计合成一对寡聚核苷酸引物(P1 5'-GAATTCATGCT G GACACGGAGGTGGC-3'和P2 5' TCTAGGATC CCAGCAACCTCCACCCCT-3'),在引物的两端引入 了EcoRI及BamHI切点.引物由赛百盛公司合成.在0.5ml的Eppendof管中依次加入17. 3μl双蒸水,2.5μl的10×缓冲液(含20mmol/L MgCl2)、2μl 2mmol/L dNTP、1μl 12.5μmmol/L P1、1μl 12.5μmmol/L P2、1μl pBRTM/HCV-1质粒、0.2μl Taq DNA聚合 酶(5 U/μl).放入PE9600PCR仪中扩增.扩增条件:94℃变性55s、62℃退火55s、72℃延伸90s,循环30次后,72℃保温7min.1%琼脂糖凝胶电泳鉴定扩增结果.②pGBKT7-NS2的构建与鉴定:将酚/氯仿抽提、乙醇沉淀的上述PCR反应产物与pGEM-T载体按3∶1mol/L混合,在16℃条件下用T4 DNA连接酶连接过夜,随后转化用氯化钙法制备的大肠杆菌DH5α感受态细胞.在铺有IPTG及X-β-Gal的氨苄西林平板上进行蓝白菌落筛选,挑取白色菌落用碱裂解法提取质粒DNA进行酶切鉴定及测序.证明HCV NS2蛋白基因已被克隆进T载体.此质粒及pGBKT7均用EcoRI及BamHI酶切,在T载体上释放的HCV NS2蛋白基因用上述相同的方法连接到pGBKT7,随机挑取卡那霉素平板上生长的菌落,碱裂解法抽提其质粒DNA,进行双酶切及PCR鉴定.③pGBKT7-NS2转化AH109酵母细胞:用醋酸锂法转化,按Clontech公司提供的说明书进行,转化后铺板于SD/-Trp进行筛选.④挑取2~3mm大小的菌落过夜培养后,提取酵母蛋白质,操作步骤按Clontech公司提供的说明书进行.⑤表达产物的十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和Western免疫印迹分析均按常规方法进行[20].由于我们所表达蛋白为带有人c-myc标签的融合蛋白,此标签为酵母表达载体所带有,所以所用抗体为抗人c-myc单克隆抗体[21].

    2 结果

    2.1 载体构建
HCV NS2蛋白基因的扩增和pGBKT7-NS2重组质粒 的构建(图1).

    1 pGBKT7-NS2重组质粒图

    2.2 pGBKT7-NS2重组质粒酶切鉴定 利用自行设计的引 物P1\P2成功扩增出HCV NS2基因片段,PCR产物经1%琼脂糖凝胶电泳分析显示扩增片段约654bp,与预期片段符合,且无非特异扩增现象.用PCR扩增的HCV NS2基因测序结果显 示序列正确.用双酶切所得片段,连接到用相同的EcoRI及BamHI所切的pGBKT7中经酶切鉴定所获结果正确(图2).

    2 pGBKT7-NS2 EcoRI及BamHI酶切鉴定

    由此表明HCV NS2基因已按正确方向克隆入酵母表达载体pGBKT7中,pGBKT7-NS2质粒构建成 功.

    2.3 pGBKT7-NS2质粒转化酵母AH109株 用醋酸锂法转化酵母后在SD/-Trp培养基上筛选生长.由于AH109株为色氨酸营养缺陷,质粒pGBKT7中 带有色氨酸基因,转化成功的AH109可以在缺少色氨酸的培养基上生长.培养数天后,挑取 一菌落进行PCR扩增NS2蛋白基因.结果显示转化成功.

    2.4 表达产物的SDS-PAGE和Western免疫印迹分析 提 取未转化质粒与转化了质粒的酵母蛋白质,进行SDS-PAGE和Western免疫印迹分析结果(图3).

    3 NS2 Western Blotting

    1:NS2蛋白,相对分子量为23kDa;2:阳性对照肝再生增强因子(ALR)

    结果显示对照无表达而转化了pGBKT7-NS2的酵母蛋白提取物Western印迹分析可见明显条带 且无杂带,SDS-PAGE胶电泳条带计算机分析表明其表达量占总蛋白量的4%左右.

    3 讨论关于HCV NS2蛋白的研究显示,NS2蛋白没有独立的功能,其羧基末端是HCV中的NS2/NS3蛋白酶的一部分, 氨基末端作为穿膜部分,起到稳定酶活性的作用[22-25].体外研 究显示,在没有氨基末端及微体膜的情况下,其蛋白酶活性消失但是加入去污剂及锌离子与 甘油就可以恢复蛋白酶活性,从而证明这是一个金属蛋白酶而且其疏水氨基端起到固定酶作 用,自切割位点在Leu1026-Ala1027之间[18,27,28].酵母中的研究显示,其蛋 白酶活性可以在酵母细胞体内重构[29].有人认为NS2蛋白是非结构蛋白,但也有 人提出了有争议的观点认为NS2蛋白是结构蛋白[16],NS2蛋白还是推定的HCV复制复 合体的成分之一[22],所以目前NS2蛋白的性质还有待于明确,NS2蛋白与人体细胞 的相互作用还未见报道.为此我们在酵母中表达了NS2蛋白,蛋白大小符合文献报道.一些蛋白在大肠杆菌中的表达只能以融合肽的形式表达,许多真核生物的肽对于大肠杆菌是 有毒性的,或在其合成过程中降解;合成的肽有时缺乏生物活性及翻译后的修饰.大量表达 的蛋白质在原核生物的环境中形成包含体,使蛋白形成错误的折叠,需要变性复性过程,特别繁琐.而酵母是一种真核生物,对于大部分真核生物的蛋白质特别是晡乳动物的蛋白质都能在酵母细胞中正确表达与翻译后修饰,而且酵母中表达的量比在晡乳动物细胞中的量大, 原核生物表达的量也足以满足要求[30].我们为了研究HCV NS2蛋白的作用,从HCV全长基因中克隆出NS2蛋白基因,把NS2蛋白基因在 酵母表达载体pGBKT7中与c-myc标签基因片段及DNA结合域(GAL41-147氨基酸基因) 基因在酵母表达载体中融合成功并且表达,在Western免疫印迹分析时用其标签单克隆抗体 检测到大小符合融合蛋白大小的蛋白质,说明NS2融合蛋白在酵母中表达成功.表达产物存在于酵母细胞内.随着基因组计划的完成,以后的研究进入了后基因组阶段[30-36],pGBKT7-NS2 酵母双杂交融合蛋白“饵”表达系统的建立,为研究HCV NS2蛋白与细胞内蛋白的相互作用 奠定了基础,对深入了解HCV NS2蛋白的结构与功能以及在人体中对宿主细胞的作用提供帮 助.

    4 REFERENCES1 Choo QL, Kuo G, Weiner AJ, Bradley DW, Houghton M. Isolation of a cD NA clone derived from a blood-borne non-A non-B viral

    hepatitis genome. Sci ence 1989;244:359-362

    2 Kuo G, Choo QL, Alter HJ, Gitnick GL, Redecker AG, Purcell RH, Myamura TJ, Di enstag L, Alter MJ, Stevens CE, Tagtmeier GE,Bonino F, Colombo M, Lee WS, Kuo C , Berger K, Shister JR, Overby LR, Bradley DW, Houghton M. An assay for circulating

    antibodies to a major etiologic virus of human non-A non-B hepatitis. Sc ience 1989;244:362-364

    3 Assy N, Minuk GY. A comparison between previous and present histologic assess ments of chronic hepatitis C viral infections in

    humans. World J Gastroenterol 1999;5:107-110

    4 Huang F, Zhao GZ, Li Y. HCV genotypes in hepatitis C patients and their clini cal significances. World J Gastroenterol 1999;5:547-549

    5 Deng ZL, Ma Y, Yuan L, Teng PK. The importance of hepatitis C as a risk facto r for hepatocellular carcinoma in Guangxi.

    World J Gastroenterol 2000;6(Supp l 3):75

    6 Song ZQ, Hao F, Min F, Ma QY, Liu GD. Hepatitis C virus infection of human he patoma cell line 7721 in vitro.

    World J Gastroenterol 2001;7:685-689

    7 Zhang LF, Peng WW, Yao JL, Tang YH. Immunohistochemical detection of HCV infe ction in patients with hepatocellular carcinoma

    and other liver diseases. Worl d J Gastroenterol 1998;4:64-65

    8 Yang JM, Wang RQ, Bu BG, Zhou ZC, Fang DC, Luo YH. Effect of HCV infection o n expression of several cancer associated gene

    products in HCC. World J Gastro enterol 1999;5:25-27

    9 Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Med ina-Selby A, Barr PJ, Weiner AJ, Bradley DW, Kuo G,Houghton M. Genetic organiz ation and diversity of the hepatitis C virus. Proc Natl Acad Sci 1991;88:2451-2455

    10 Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expressi on and identification of hepatitis C virus polyprotein products.

    J Virol 199 3;67:1385-1395

    11 Grakoui A, McCourt DW, Wychowski C, Feinstone S, Rice CM. Characteriza tion of hepatitis C virus-encoded serine proteinase:

    determination of proteinas e-dependent polyprotein cleavage sites. J Virol 1993;67:2832-2843

    12 Houghton M,Weiner A,Han J,Kuo G,Choo QL. Molecular biology of the hepa titis C viruses:implication for diagnosis, development

    and control of viral dise ase.Hepatology 1991;14:381-388

    13 Selby MJ, Choo QL, Berger K, Kuo G, Glazer E, Eckart M, Lee C, Chien D, Kuo C, Houghton M. Expression, identification and

    subcellular localization of the proteins encoded by the hepatitis C virus. J Gen Virol 1993;74:110-1113

    14 Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onoshi E, Andoh T, Yoshida I, Okayama H. Structure and

    organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991;65:1105-1113

    15 Gao JE, Tao QM, Guo JP, Ji HP, Lang ZW, Ji Y, Feng BF. Preparation and application of monoclonal antibodies against hepatitis

    C virus nonstructural pr oteins. China Natl J New Gastroenterol 1997;3:114-116

    16 Santolini E, Pacini L, Fipaldini C, Migliaccio G, La Monica N. The NS2 protein of hepatitis C virus is a transmembrane polypeptide.

    J Virol 1995; 69:7461-7471

    17 Grakoui A, McCourt C, Wychowski S, Feinstone M, Rice CR. A second hep atitis C virus-encoded proteinase.

    Proc Natl Acad Sci 1993;90:10583-10587

    18 Pieroni L, Santokini E, Fipaldini C, Pacini L, Migliaccio G, Monica NL . In vitrol study of the NS2-3 protease of hepatitis C virus.

    J Virol 1997; 71:6373-6380

    19 Berg JM, Shi Y. The galvanization of biology: a growing appreciation f or the roles of zinc. Science 1996;271:1081-1085

    20 Jin D, Li MF. Molecular Cloning: A Laboratory Manual. 2nd ed. Beijing .Scientific press 1992:880-897

    21 Evan GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibo dies specific for human c-myc proto-oncogene product.

    Mol Cell Biol 19 85;5:3610-3616

    22 Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T , Kimura K, Shimotohno K. Two distinct proteinase activities

    required for the pr ocessing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 1993;67:4665-4675

    23 Hijikata M, Mizushima H, Akagi T, Tanji Y, Komoda Y, Hirowatari Y, Aka gi T, Kato N, Kimura K, Shimotohno K. Proteolytic

    processing and membrane associ ation of putative nonstructural proteins of hepatitis C virus.

    Proc Natl Acad Sci 1993;90:10773-10777

    24 De Francesco R, Urbani A, Nardi MC, Tomei L, Steinkuhler C, Tramontano A. A zinc binding site in viral serine proteinases.

    Biochemistry 1996;35:13282-13287

    25 Eckart MR, Selby M, Maisiarz F, Lee C, Berger K, Crawford K, Kuo C, Ku o G, Houghton M, Choo QL. The hepatitis C virus encodes

    a serine protease involv ed in processing of the putative nonstructural proteins from the viral polyprotein precursor.

    Biochem Biophys Res Commun 1993;192:399-406

    26 Reed KE, Grakoui A, Rice CM. Hepatitis C virus-encoded NS2-3 proteas e: cleavage site mutagenesis and requirements for

    bimolecular cleavage. J Viro l 1995;69:4127-4136

    27 Thibeault D, Maurice R, Pilote L, Lamarre D, Pause A. In Vitro Charact erization of a Purified NS2/3 Protease Variant of Hepatitis

    C Virus. J Biol Ch em 2001;276:46678-46684

    28 Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Kinetic and st ructural analyses of hepatitis C virus polyprotein processing.

    J Virol 1994; 68:5045-5055

    29 Mak P, Palant O, Labonte P, Plotch S. Reconstitution of hepatitis C vi rus protease activities in yeast. FEBS Lett 2001;503:13-18

    30 DeWan AT, Parrado AR, Matise TC, Leal SM. The map problem: a compariso n of genetic and sequence-based physical maps.

    Am J Hum Genet 2002;70:101- 107

    31 Capron AM. Human genome research in an interdependent world. Kennedy Inst Ethics J 1991;1:247-251

    32 Trent RJ. Milestones in the Human Genome Project: genesis to postgenom e. Med J Aust 2000;173:591-594

    33 Idle JR, Corchero J, Gonzalez FJ. Medical implications of HGP's sequen ce of chromosome 22. Lancet 2000;355:319

    34 Rice E. The Human Genome Project and gene therapy: a genetic counselor 's perspective. J Perinat Neonatal Nurs 1998;12:16-25

    35 vans GA. The Human Genome Project: applications in the diagnosis and t reatment of neurologic disease.

    Arch Neurol 1998;55:1287-1290

    36 elavkar U, Shah K. Advances in the Human Genome Project. Mol Biol Re p 1998;25:27-43, http://www.100md.com(李 克, 王 琳, 成 军, 陆荫英, 张玲霞, 李 莉, 刘 妍, 段惠娟)